{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:39:03Z","timestamp":1757705943754},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T00:00:00Z","timestamp":1372896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00198-013-2428-0","type":"journal-article","created":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T09:59:40Z","timestamp":1372845580000},"page":"773-776","source":"Crossref","is-referenced-by-count":2,"title":["Can long-term bisphosphonate use causes low-energy fractures? A case report"],"prefix":"10.1007","volume":"25","author":[{"given":"T.","family":"Dandino\u011flu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Akarsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Karadeniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Tekin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ar\u0131bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Z.","family":"K\u0131ralp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,4]]},"reference":[{"key":"2428_CR1","volume-title":"Osteoporosis diagnosis, prevention, therapy","author":"R Bartl","year":"2009","unstructured":"Bartl R, Frisch B (2009) Osteoporosis diagnosis, prevention, therapy, 2nd edn. Springer, Berlin","edition":"2"},{"key":"2428_CR2","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"issue":"5","key":"2428_CR3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","volume":"28","author":"T Mashiba","year":"2001","unstructured":"Mashiba T, Turner CH, Hirano T et al (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28(5):524\u2013531","journal-title":"Bone"},{"key":"2428_CR4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","volume":"20","author":"BA Lenart","year":"2009","unstructured":"Lenart BA, Neviaser AS, Lyman S et al (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353\u20131362","journal-title":"Osteoporos Int"},{"issue":"9","key":"2428_CR5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/00002018-200932090-00002","volume":"32","author":"K Ing-Lorenzini","year":"2009","unstructured":"Ing-Lorenzini K, Desmeules J, Plachta O et al (2009) Low energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 32(9):775\u2013785","journal-title":"Drug Saf"},{"issue":"12","key":"2428_CR6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(12):1189\u20131199","journal-title":"N Engl J Med"},{"issue":"6","key":"2428_CR7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","volume":"75","author":"LG Ste-Marie","year":"2004","unstructured":"Ste-Marie LG, Sod E, Johnson T et al (2004) Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75(6):469","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"2428_CR8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","volume":"22","author":"RD Chapurlat","year":"2007","unstructured":"Chapurlat RD, Arlot M, Burt-Pichat B et al (2007) Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22(10):1502\u20131509","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2428_CR9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s002230010036","volume":"69","author":"J Li","year":"2001","unstructured":"Li J, Mashiba T, Burr DB (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69(5):281\u2013286","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2428_CR10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00223-005-1295-x","volume":"77","author":"T Mashiba","year":"2005","unstructured":"Mashiba T, Hui S, Turner CH et al (2005) Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif Tissue Int 77(3):180\u2013185","journal-title":"Calcif Tissue Int"},{"key":"2428_CR11","first-page":"349","volume":"89","author":"SK Goh","year":"2007","unstructured":"Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349\u2013353","journal-title":"J Bone Joint Surg Br"},{"key":"2428_CR12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","volume":"39","author":"EB Kwek","year":"2008","unstructured":"Kwek EB, Goh SK, Koh JS et al (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224\u2013231","journal-title":"Injury"},{"issue":"6","key":"2428_CR13","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1359\/jbmr.081247","volume":"24","author":"B Abrahamsen","year":"2009","unstructured":"Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24(6):1095","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2428_CR14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jama.2011.190","volume":"305","author":"LY Park-Wyllie","year":"2011","unstructured":"Park-Wyllie LY, Mamdani MM, Juurlink DN et al (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305(8):783","journal-title":"JAMA"},{"issue":"11","key":"2428_CR15","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(11):2267","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2428_CR16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/230949901101900323","volume":"19","author":"ZH Tang","year":"2011","unstructured":"Tang ZH, Kumar VP (2011) Alendronate-associated ulnar and tibial fractures: a case report. J Orthop Surg Hong Kong 19(3):370\u2013372","journal-title":"J Orthop Surg Hong Kong"},{"issue":"2","key":"2428_CR17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","volume":"21","author":"DC Bauer","year":"2006","unstructured":"Bauer DC, Garnero P, Hochberg MC et al (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21(2):292\u2013299","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2428-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-013-2428-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2428-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:08:55Z","timestamp":1558624135000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-013-2428-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["2428"],"URL":"https:\/\/doi.org\/10.1007\/s00198-013-2428-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,4]]}}}